毒扁豆碱预防肝脏手术术后谵妄与长期认知功能障碍:双盲随机对照试验
该双盲随机安慰剂对照试验纳入261例择期肝脏手术患者,比较术中诱导后24小时静脉输注毒扁豆碱与安慰剂对术后谵妄(POD)和术后认知功能障碍(POCD)的影响。结果显示毒扁豆碱未显著降低POD发生率(20% vs 15%,P=0.334),各时间点POCD频率也无显著差异,但毒扁豆碱组3个月和6个月死亡率较低。
要点
- 毒扁豆碱未降低肝脏手术患者POD发生率(20% vs 15%,P=0.334)。
- 毒扁豆碱未改善术后7、90、365天的POCD频率。
- 毒扁豆碱组3个月和6个月死亡率低于安慰剂组。
核心结论
- 麻醉诱导后24小时内给予毒扁豆碱对POD和POCD无显著影响。
研究设计与样本
- 双盲随机安慰剂对照试验,单中心学术医疗中心开展,2009年8月11日至2016年3月3日招募。
- 共261例≥18岁择期肝脏手术患者随机分配至毒扁豆碱组(n=130)或安慰剂组(n=131),另设45例非手术匹配对照提供POCD和神经认知缺陷的常模数据。
- 毒扁豆碱用法:诱导麻醉后静脉给予0.02 mg/kg负荷量,继以0.01 mg/kg/h维持24小时。
- 随访时间点为术后1周(T1)、90天(T2)和365天(T3)。
主要发现
- POD发生率毒扁豆碱组20%、安慰剂组15%,差异无统计学意义(P=0.334)。
- 术前认知障碍及POCD频率在毒扁豆碱组与安慰剂组各时间点均无显著差异。
- 术后3个月死亡率毒扁豆碱组2%(95%CI 0-4)vs 安慰剂组11%(95%CI 6-16),P=0.002。
- 术后6个月死亡率毒扁豆碱组7%(95%CI 3-12)vs 安慰剂组16%(95%CI 10-23),P=0.012。
关键数值与推荐
- POD评估采用DSM-4-TR标准,术后7天内每日两次。
- POCD评估采用CANTAB神经心理测试组合及两项纸笔测试,于术前一天及术后第7、90、365天进行。
临床怎么用
- 不推荐为预防POD或POCD而在肝脏手术中常规使用毒扁豆碱。
- 毒扁豆碱组死亡率较低的发现需进一步研究验证,不能作为临床常规依据。
局限性
- 单中心研究,结论外推需谨慎。
- 原文未报告样本量计算的细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anecdotally, cholinergic stimulation has been used to treat delirium and reduce cognitive dysfunction. OBJECTIVE: The aim of this investigation was to evaluate whether physostigmine reduced the incidence of postoperative delirium (POD) and postoperative cognitive dysfunction (POCD) in patients undergoing liver resection. DESIGN: This was a double-blind, randomised, placebo-controlled trial. Between 11 August 2009 and 3 March 2016, patients were recruited at the Charité - Universitätsmedizin Berlin in Germany. Follow-ups took place at 1 week (T1), 90 days (T2) and 365 days (T3) after surgery. SETTING: This single-centre study was conducted at an academic medical centre. PARTICIPANTS: In total, 261 participants aged at least 18 years scheduled for elective liver surgery were randomised. The protocol also included 45 non-surgical matched controls to provide normative data for POCD and neurocognitive deficit (NCD). INTERVENTION: Participants were allocated to receive either intravenous physostigmine, as a bolus of 0.02 mg kg-1 body weight followed by 0.01 mg kg-1 body weight per hour (n = 130), or placebo (n = 131), for 24 h after induction of anaesthesia. MAIN OUTCOMES AND MEASURES: Primary outcomes were POD, assessed using the Diagnostic and Statistical Manual of Mental Disorders (DSM-4-TR) twice daily up to day 7 after surgery, and POCD assessed via the CANTAB neuropsychological test battery, and two paper pencil tests on the day before surgery, and on postoperative days 7, 90 and 365. RESULTS: In total, 261 patients were randomised, 130 to the physostigmine and 131 to the placebo group. The incidence of POD did not differ significantly between the physostigmine and placebo groups (20 versus 15%; P = 0.334). Preoperative cognitive impairment and POCD frequencies did not differ significantly between the physostigmine and placebo groups at any time. Lower mortality rates were found in the physostigmine group compared with placebo at 3 months [2% (95% confidence interval (CI), 0 to 4) versus 11% (95% CI, 6 to 16), P = 0.002], and 6 months [7% (95% CI, 3 to 12) versus 16% (95% CI, 10 to 23), P = 0.012] after surgery. CONCLUSION: Physostigmine had no effect on POD and POCD when applied after induction of anaesthesia up to 24 h. TRIAL REGISTRATION: DOI 10.1186/ISRCTN18978802, EudraCT 2008-007237-47, Ethics approval ZS EK 11 618/08 (15 January 2009).
引用
- Spies CD, Knaak C, Mertens M, et al. Physostigmine for prevention of postoperative delirium and long-term cognitive dysfunction in liver surgery: A double-blinded randomised controlled trial. Eur J Anaesthesiol. 2021. PMID: 33534264. doi:10.1097/EJA.0000000000001456
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。